The gBRCA testing in TNBC/HER2-negative BC patients is potentially cost-effective
The cost-effectiveness of the first-line use of PARPi or the universal testing in the general population of BC is not convincing [Elvira et al. found no evidence of cost-effectiveness for gBRCA testing among all newly diagnosed BC followed by cascade testing of relatives [